Patent ID: 7655444
Filing Date: 2010-02-02
Classification: C07K,C12Q,Y10S

Abstract:
1. A method for predicting a clinical response to treatment with an alkylating chemotherapeutic agent of a human subject in need thereof, wherein clinical response is measured by tumor regression, disease-free survival, or survival, comprising: obtaining a nucleic acid from a brain tumor or a diffuse large B-cell lymphoma of the subject to be treated; treating the nucleic acid sample with bisulfite to modify unmethylated cytosine residues in the nucleic acid sample; determining the state of methylation of the promoter of the O comparing the state of methylation with the state of MGMT promoter methylation from an unmethylated control sample; and predicting the clinical response of the subject in need of treatment based on the comparison, wherein hypermethylation of the MGMT promoter of the subject in need of treatment, as compared with the state of MGMT promoter methylation from an unmethylated control sample, is indicative of increased tumor regression, increased disease-free survival, and increased survival, in response to treatment with an alkylating chemotherapeutic agent.